DeutschNewstral
Article
jdsupra.com on 2016-02-04 15:20
ICYMI: Biosimilars and FDA Regulatory Webinar
Related news
- [Webinar] Biologics and Biosimilars: Development with an Eye Towards FDA Approval - February 17th, 10:00am PST/1:00pm ESTjdsupra.com
- FDA Webinar To Discuss the Regulatory Framework and the Development and Approval of Biosimilar Products in the U.S.jdsupra.com
- FDA Committee Recommends Approval of Bevacizumab and Trastuzumab Biosimilarsjdsupra.com
- FDA and FTC Join Forces to Promote Biosimilarsjdsupra.com
- FDA and FTC Announce Collaboration to Support Biosimilars Marketjdsupra.com
- Webinar PowerPoint Slides: Medical Apps and Devices: The Convergence of FDA, FTC, and State and Federal Regulationsjdsupra.com
- FDA Releases Biosimilars Educational Materialsjdsupra.com
- FDA Releases Biosimilars Action Planjdsupra.com
- FDA Continues to Approve Biosimilarsjdsupra.com
- FDA Approves Sandoz Denosumab Biosimilarsjdsupra.com
- Coherus and Xbrane Announce Acceptance of Regulatory Submissions for Ranibizumab Biosimilarsjdsupra.com
- [Event] Biosimilars Summit – Legal, Regulatory, and Commercial Strategies – June 24th-25th, New York City, NYjdsupra.com
- How to navigate gene editing regulatory hurdles: FDA webinar clarifies newly finalized guidancejdsupra.com
- ICYMI: Ediscovery in China [Webinar]jdsupra.com
- Four new FDA guidances and proposed rule advance biosimilars policy frameworkjdsupra.com
- New Draft Guidance on FDA Meetings, But Nothing Further on Substantive Requirements for Biosimilars and Interchangeablesjdsupra.com
- FDA Publishes Biosimilars Action Plan (BAP)jdsupra.com
- FDA to Unveil Biosimilars Action Plan (BAP)jdsupra.com
- FDA Study Finds Biosimilars Are Interchangeablejdsupra.com
- FDA Regulatory and Compliance Monthly Recap – May 2015jdsupra.com